LONDON (Reuters) Jun 27 –
The European Medicines Evaluation Agency (EMEA) said on Thursday that the benefits of the anti-obesity drug sibutramine (Reductil; Abbott Laboratories Inc) were greater than its risks, but it would continue monitoring the product
. The agency said its scientific committee would keep Reductil, also known as Meridia, under review and would follow up on a safety and efficacy trial it asked Abbott to do in 2000.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!